RxDoctor Payments Data

F Mueller, MD

Psychiatry · Stamford, CTNPI 1497763080

Payments from drug & device makers

$7,548in general payments, 2019–2025

Across 402 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$981
  • Lundbeck LLC$896
  • Otsuka America Pharmaceutical, Inc.$829
  • Takeda Pharmaceuticals U.S.A., Inc.$689
  • Alkermes, Inc.$418
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$7,45899%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,548 in reported general payments places this provider in the 85th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$120,135
Medicare patients
200
Services billed
1,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole21$45,410
Clozapine OdtClozapine26$24,302
LybalviOlanzapine/Samidorphan Malate12$22,038
ParnateTranylcypromine Sulfate11$14,981
VyvanseLisdexamfetamine Dimesylate29$11,032
Bupropion XlBupropion Hcl302$9,252
TrintellixVortioxetine Hydrobromide11$9,053
RisperdalRisperidone12$8,855
Estazolam55$5,162
Alprazolam438$4,241
Escitalopram Oxalate281$4,223
Vilazodone Hcl30$4,037
Duloxetine Hcl171$3,836
Clonazepam325$3,357
Mirtazapine159$3,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$829$45,41021 claims
Alkermes, Inc.Lybalvi$418$22,03812 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$689$20,08540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →